Breast Cancer | Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Featuring an interview with Dr Joyce O'Shaughnessy, including the following topics:

• Overview of CDK Inhibition for Metastatic Breast Cancer (0:00)
• Features of High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (7:45)
• Sequencing and Selection of CDK4/6 Inhibitors (23:28)
• Management of Toxicities Associated with CDK Inhibitors and Promoting Patient Adherence (45:47)
• Review of Clinical Investigator Survey Results (1:01:47)

CME information and select publications